This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
moving-average-crossover: Archive
CoreCard (CCRD) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoreCard (CCRD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CCRDNegative Net Change ALLTNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Viant (DSP) Moves 7.2% Higher: Will This Strength Last?
by Zacks Equity Research
Viant (DSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
DSPNegative Net Change DUOLNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
After Golden Cross, Invesco (IVZ)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IVZNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Genius Sports Limited (GENI) Moves 10.6% Higher: Will This Strength Last?
by Zacks Equity Research
Genius Sports Limited (GENI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
GENIPositive Net Change YELPNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Peloton (PTON) Soars 18.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Peloton (PTON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PTONNegative Net Change ASNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Transportadora De Gas Ord B (TGS) Moves 7.9% Higher: Will This Strength Last?
by Zacks Equity Research
Transportadora De Gas Ord B (TGS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
TGSNegative Net Change PBAPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TRDANegative Net Change BCYCNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Should You Buy Medpace (MEDP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MEDPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Resideo Technologies (REZI) Surges 16.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Resideo Technologies (REZI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
REZINegative Net Change CDRENegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Strength Seen in Marvell (MRVL): Can Its 7.1% Jump Turn into More Strength?
by Zacks Equity Research
Marvell (MRVL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MRVLNegative Net Change AAOINegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Watts Water (WTS) Surges 3.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Watts Water (WTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
WTSNegative Net Change THRNegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
nLight (LASR) Moves 7.0% Higher: Will This Strength Last?
by Zacks Equity Research
nLight (LASR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
LASRNegative Net Change LSCCNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Arteris (AIP) Moves 12.2% Higher: Will This Strength Last?
by Zacks Equity Research
Arteris (AIP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AIPNegative Net Change PCTYNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
PTCTPositive Net Change PRTANegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
TEMENOS GROUP (TMSNY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TMSNYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
TransAlta (TAC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TACPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PRMEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regions Financial (RF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BRP (DOOO) Soars 7.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
BRP (DOOO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
DOOONegative Net Change ALSNNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Strength Seen in CyberArk (CYBR): Can Its 13.5% Jump Turn into More Strength?
by Zacks Equity Research
CyberArk (CYBR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CYBRPositive Net Change PANWNegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Nice (NICE) Moves 4.9% Higher: Will This Strength Last?
by Zacks Equity Research
Nice (NICE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NICENegative Net Change VERXNegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Should You Buy AppFolio (APPF) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
APPFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
F.N.B. (FNB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FNBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMGNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Strength Seen in ProDex (PDEX): Can Its 8.2% Jump Turn into More Strength?
by Zacks Equity Research
ProDex (PDEX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PDEXNegative Net Change MCKPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today